Observational study to evaluate the clinical benefit of lamotrigine add-on therapy in bipolar patients in a naturalistic treatment setting

Asia-Pacific Psychiatry

Volumn 6, Issue 3, 2014, Pages 334-341

  Woo, Young Sup ^a   Bahk, Won Myong ^a   Pae, Chi Un ^a   Jeong, Jong Hyun ^a   Koo, Bon Hoon ^b   Jon, Duk In ^c   Lee, Jung Goo ^d   Kim, Moon Doo ^e  

^a The Catholic University of Korea   (South Korea)

^b Yeungnam University College of Medicine   (South Korea)

^c Hallym University   (South Korea)

^d Inje University   (South Korea)

^e Jeju National University School of Medicine   (South Korea)

Author keywords

Add on therapy; Bipolar disorder; Clinical benefit; Lamotrigine

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; BENZODIAZEPINE DERIVATIVE; LAMOTRIGINE; LITHIUM; OLANZAPINE; PALIPERIDONE; QUETIAPINE; RISPERIDONE; VALPROIC ACID; ZIPRASIDONE; ANTICONVULSIVE AGENT; NEUROLEPTIC AGENT; TRANQUILIZER; TRIAZINE DERIVATIVE;

ADD ON THERAPY; ADULT; AGITATION; ARTICLE; BIPOLAR I DISORDER; BIPOLAR II DISORDER; BLURRED VISION; CLINICAL EVALUATION; CLINICAL GLOBAL IMPRESSION CLINICAL BENEFIT SCALE; CLINICAL GLOBAL IMPRESSION OF BIPOLAR DISORDER SEVERITY SCALE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED STUDY; DAYTIME SOMNOLENCE; DROWSINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG TOLERANCE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PERMISSIBLE DOSE; MENTAL PATIENT; NATURALISTIC INQUIRY; NAUSEA; NERVOUSNESS; OBSERVATIONAL STUDY; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOPHARMACOTHERAPY; RATING SCALE; SIDE EFFECT; WEIGHT GAIN; BIPOLAR DISORDER; DRUG POTENTIATION; EVALUATION STUDY; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; ANTICONVULSANTS; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DRUG SYNERGISM; FEMALE; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME; TRIAZINES;

EID: 84924137079     PISSN: 17585864     EISSN: 17585872     Source Type: Journal    
DOI: 10.1111/appy.12095     Document Type: Article

References (34)

1. Bauer M., Glenn T., Grof P., Schmid R., Pfennig A., Whybrow P.C. (2010) Subsyndromal mood symptoms: a useful concept for maintenance studies of bipolar disorder. Psychopathology. 43, 1-7.
2. Bauer M., Ritter P., Grunze H., Pfennig A. (2012) Treatment options for acute depression in bipolar disorder. Bipolar Disord. 14(Suppl 2), 37-50.
3. Bauer M.S., Kirk G.F., Gavin C., Williford W.O. (2001) Determinants of functional outcome and healthcare costs in bipolar disorder: a high-intensity follow-up study. J Affect Disord. 65, 231-241.
4. Bowden C.L., Calabrese J.R., McElroy S.L., etal. (1999) The efficacy of lamotrigine in rapid cycling and non-rapid cycling patients with bipolar disorder. Biol Psychiatry. 45, 953-958.
5. Bowden C.L., Singh V. (2012) Lamotrigine (Lamictal IR) for the treatment of bipolar disorder. Expert Opin Pharmacother. 13, 2565-2571.
6. Calabrese J.R., Bowden C.L., Sachs G.S., Ascher J.A., Monaghan E., Rudd G.D. (1999) A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry. 60, 79-88.
7. Calabrese J.R., Suppes T., Bowden C.L., etal. (2000) A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group. J Clin Psychiatry. 61, 841-850.
8. Calabrese J.R., Shelton M.D., Rapport D.J., Kimmel S.E. (2002) Bipolar disorders and the effectiveness of novel anticonvulsants. J Clin Psychiatry. 63(Suppl 3), 5-9.
9. Calabrese J.R., Huffman R.F., White R.L., etal. (2008) Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disord. 10, 323-333.
10. Denicoff K.D., Smith-Jackson E.E., Disney E.R., etal. (1997) Preliminary evidence of the reliability and validity of the prospective life-chart methodology (LCM-p). J Psychiatr Res. 31, 593-603.
11. Dion G.L., Tohen M., Anthony W.A., Waternaux C.S. (1988) Symptoms and functioning of patients with bipolar disorder six months after hospitalization. Hosp Community Psychiatry. 39, 652-657.
12. Frye M.A., Yatham L.N., Calabrese J.R., etal. (2006) Incidence and time course of subsyndromal symptoms in patients with bipolar I disorder: an evaluation of 2 placebo-controlled maintenance trials. J Clin Psychiatry. 67, 1721-1728.
13. Gajwani P., Forsthoff A., Muzina D., etal. (2005) Antiepileptic drugs in mood-disordered patients. Epilepsia. 46(Suppl 4), 38-44.
14. Ganesan S., Agambaram V., Randeree F., Eggens I., Huizar K., Meulien D. (2008) Switching from other antipsychotics to once-daily extended release quetiapine fumarate in patients with schizophrenia. Curr Med Res Opin. 24, 21-32.
15. Garnham J., Munro A., Slaney C., etal. (2007) Prophylactic treatment response in bipolar disorder: results of a naturalistic observation study. J Affect Disord. 104, 185-190.
16. Geddes J.R., Calabrese J.R., Goodwin G.M. (2009) Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry. 194, 4-9.
17. Goodwin G.M. (2009) Evidence-based guidelines for treating bipolar disorder: revised second edition-recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 23, 346-388.
18. Goodwin G.M., Bowden C.L., Calabrese J.R., etal. (2004) A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry. 65, 432-441.
19. Guy W. (1976) ECDEU Assessment Manual for Psychopharmacology. National Institute of Mental Health: US Dept Health, Education, and Welfare, Rockville, MD.
20. Judd L.L., Akiskal H.S., Schettler P.J., etal. (2002) The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 59, 530-537.
21. Judd L.L., Akiskal H.S., Schettler P.J., etal. (2003a) A prospective investigation of the W natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry. 60, 261-269.
22. Judd L.L., Akiskal H.S., Schettler P.J., etal. (2003b) The comparative clinical phenotype and long term longitudinal episode course of bipolar I and II: a clinical spectrum or distinct disorders. J Affect Disord. 73, 19-32.
23. Judd L.L., Akiskal H.S., Schettler P.J., etal. (2005) Psychosocial disability in the course of bipolar I and II disorders: a prospective, comparative, longitudinal study. Arch Gen Psychiatry. 62, 1322-1330.
24. Keck P.E., Jr, McElroy S.L. (2003) Redefining mood stabilization. J Affect Disord. 73, 163-169.
25. Lee J.G., Yoon Y.B., Jon D.I., etal. (2011) Korean medication algorithm for bipolar disorder 2010: maintenance therapy. J Korean Soc Dep Bipolar Disord. 9, 162-170.
26. MacQueen G.M., Marriott M., Begin H., Robb J., Joffe R.T., Young L.T. (2003) Subsyndromal symptoms assessed in longitudinal, prospective follow-up of a cohort of patients with bipolar disorder. Bipolar Disord. 5, 349-355.
27. Marangell L.B. (2004) The importance of subsyndromal symptoms in bipolar disorder. J Clin Psychiatry. 65(Suppl 10), 24-27.
28. Martinez-Aran A., Vieta E., Torrent C., etal. (2007) Functional outcome in bipolar disorder: the role of clinical and cognitive factors. Bipolar Disord. 9, 103-113.
29. Min K.J., Bahk W.M., Yoon B.H., etal. (2011) Korean medication algorithm for bipolar disorder 2010: introduction. Korean J Psychopharmacol. 22, 142-153.
30. Paykel E.S., Abbott R., Morriss R., Hayhurst H., Scott J. (2006) Sub-syndromal and syndromal symptoms in the longitudinal course of bipolar disorder. Br J Psychiatry. 189, 118-123.
31. Spearing M.K., Post R.M., Leverich G.S., Brandt D., Nolen W. (1997) Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res. 73, 159-171.
32. Suppes T., Dennehy E.B., Hirschfeld R.M., etal. (2005) The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry. 66, 870-886.
33. Vieta E., Locklear J., Gunther O., etal. (2010) Treatment options for bipolar depression: a systematic review of randomized, controlled trials. J Clin Psychopharmacol. 30, 579-590.
34. Yatham L.N., Kennedy S.H., Schaffer A., etal. (2009) Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord. 11, 225-255.